## Min Soo Park

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4500336/publications.pdf

Version: 2024-02-01

489802 511568 1,254 123 18 30 citations h-index g-index papers 132 132 132 2104 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	The impact of neonatal morbidities on child growth and developmental outcomes in very low birth weight infants: a nationwide cohort study. European Journal of Pediatrics, 2022, 181, 197-205.	1.3	5
2	Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone. Clinical Pharmacology in Drug Development, 2022, 11, 576-584.	0.8	1
3	Clinical Usefulness of Regional Tissue Oxygen Saturation Monitoring Using Near-Infrared Spectroscopy in Neonates. Perinatology, 2022, 33, 21.	0.0	O
4	Association between bronchopulmonary dysplasia and early respiratory morbidity in children with respiratory distress syndrome: a case–control study using nationwide data. Scientific Reports, 2022, 12, 7578.	1.6	2
5	Growth Pattern With Morbidities From Birth to 5 Years of Age in Very Low Birth Weight Infants: Comparison of the Korean National Network and National Health Insurance Service. Journal of Korean Medical Science, 2022, 37, .	1.1	2
6	Application of Machine Learning Approaches to Predict Postnatal Growth Failure in Very Low Birth Weight Infants. Yonsei Medical Journal, 2022, 63, 640.	0.9	4
7	Tools for assessing lung fluid in neonates with respiratory distress. BMC Pediatrics, 2022, 22, .	0.7	4
8	Identification of Growth Patterns in Low Birth Weight Infants from Birth to 5 Years of Age: Nationwide Korean Cohort Study. International Journal of Environmental Research and Public Health, 2021, 18, 1206.	1.2	6
9	Outcomes of infants born to pregnant women with syphilis: a nationwide study in Korea. BMC Pediatrics, 2021, 21, 47.	0.7	11
10	Adequacy of safety data for regulatory approval of pediatric indication through extrapolation algorithm. Translational and Clinical Pharmacology, 2021, 29, 73.	0.3	0
11	Comparison of the pharmacokinetics and pharmacodynamics of YH4808 in healthy subjects for defining an appropriate dosing regimen. Translational and Clinical Pharmacology, 2021, 29, 150.	0.3	1
12	Pharmacokinetic equivalence of CTâ€P17 to highâ€concentration (100Âmg/ml) reference adalimumab: A randomized phase I study in healthy subjects. Clinical and Translational Science, 2021, 14, 1280-1291.	1.5	11
13	Impact of neonatal resuscitation changes on outcomesÂof very-low-birth-weight infants. Scientific Reports, 2021, 11, 9003.	1.6	3
14	Growth failure of very low birth weight infants during the first 3 years: A Korean neonatal network. PLoS ONE, 2021, 16, e0259080.	1.1	6
15	Epidemiology of Macrosomia in Korea: Growth and Development. Journal of Korean Medical Science, 2021, 36, e320.	1.1	6
16	Neonatal Type 2 Gaucher Disease with Congenital Ichthyosis: A Case Report. Perinatology, 2021, 32, 208.	0.0	0
17	Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy. Microbiology Spectrum, 2021, 9, e0063321.	1.2	5
18	Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection. Clinical Gastroenterology and Hepatology, 2020, 18, 3043-3045.e1.	2.4	26

#	Article	IF	CITATIONS
19	Pharmacokinetics and safety of evogliptin in hepatically impaired patients. British Journal of Clinical Pharmacology, 2020, 87, 2757-2766.	1.1	2
20	A Population Pharmacokinetic and Pharmacodynamic Model of CKD-519. Pharmaceutics, 2020, 12, 573.	2.0	0
21	Signal Detection of Adverse Events Following Pneumococcal Vaccines from the Korea Adverse Event Reporting System Database, 2005–2016. Yonsei Medical Journal, 2020, 61, 243.	0.9	3
22	Hearing Impairments in Preterm Infants: Factors Associated with Discrepancies between Screening and Confirmatory Test Results. Neonatal Medicine, 2020, 27, 126-132.	0.1	2
23	Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects. Translational and Clinical Pharmacology, 2020, 28, 55.	0.3	4
24	Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjects. Translational and Clinical Pharmacology, 2020, 28, 136.	0.3	4
25	Pulmonary Surfactant Replacement Therapy for Respiratory Distress Syndrome in Neonates: a Nationwide Epidemiological Study in Korea. Journal of Korean Medical Science, 2020, 35, e253.	1.1	8
26	Population pharmacokinetics of intravenous sufentanil in critically ill patients supported with extracorporeal membrane oxygenation therapy. Critical Care, 2019, 23, 248.	2.5	4
27	The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male. Drug Design, Development and Therapy, 2019, Volume 13, 3151-3159.	2.0	9
28	Comparison of acute kidney injury and clinical prognosis of vancomycin monotherapy and combination therapy with beta-lactams in the intensive care unit. PLoS ONE, 2019, 14, e0217908.	1.1	21
29	Genitopatellar Syndrome Secondary to <i>De Novo KAT6B</i> Mutation: The First Genetically Confirmed Case in South Korea. Yonsei Medical Journal, 2019, 60, 395.	0.9	2
30	Optimal birth weight and term mortality risk differ among different ethnic groups in the U.S Scientific Reports, 2019, 9, 1651.	1.6	4
31	Implementation of a Targeted Next-Generation Sequencing Panel for Constitutional Newborn Screening in High-Risk Neonates. Yonsei Medical Journal, 2019, 60, 1061.	0.9	4
32	Successful Treatment of Neonatal Pylorospasm with Intravenous Atropine. Neonatal Medicine, 2019, 26, 67-71.	0.1	2
33	Evaluation of Newborn Infants with Prenatally Diagnosed Congenital Pulmonary Airway Malformation: A Single-Center Experience. Neonatal Medicine, 2019, 26, 138-146.	0.1	1
34	Regulatory innovation for expansion of indications and pediatric drug development. Translational and Clinical Pharmacology, 2018, 26, 155.	0.3	2
35	Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers. Drug Design, Development and Therapy, 2018, Volume 12, 2381-2387.	2.0	2
36	Pharmacokinetic drug interaction and safety after coadministration of clarithromycin, amoxicillin, and ilaprazole: a randomised, open-label, one-way crossover, two parallel sequences study. European Journal of Clinical Pharmacology, 2018, 74, 1149-1157.	0.8	7

#	Article	IF	CITATIONS
37	Coagulant Effect and Tolerability of Yeast-Produced Recombinant Batroxobin in Healthy Adult Subjects. Clinical Drug Investigation, 2018, 38, 829-835.	1.1	3
38	Effective Tidal Volume for Normocapnia in Very-Low-Birth-Weight Infants Using High-Frequency Oscillatory Ventilation. Yonsei Medical Journal, 2018, 59, 101.	0.9	8
39	Population pharmacokinetic model of levetiracetam in Korean neonates with seizures. International Journal of Clinical Pharmacology and Therapeutics, 2018, 56, 217-223.	0.3	4
40	Comparison of Pharmacokinetics and Safety of a Fixed-dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects. Clinical Therapeutics, 2017, 39, 1799-1810.	1.1	12
41	Population pharmacokinetics of remifentanil in critically ill patients receiving extracorporeal membrane oxygenation. Scientific Reports, 2017, 7, 16276.	1.6	14
42	Population Pharmacokinetics and Dose Optimization of Teicoplanin during Venoarterial Extracorporeal Membrane Oxygenation. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	16
43	Abnormal neurodevelopmental outcomes are very likely in cases of bilateral neonatal arterial ischaemic stroke. Acta Paediatrica, International Journal of Paediatrics, 2017, 106, 229-235.	0.7	2
44	Comparison of pharmacokinetics and safety of fixed-dose combination of SKI306X and aceclofenac versus separate tablets in healthy subjects. Translational and Clinical Pharmacology, 2017, 25, 196.	0.3	2
45	Experience and pharmacokinetics of Levetiracetam in Korean neonates with neonatal seizures. Korean Journal of Pediatrics, 2017, 60, 50.	1.9	13
46	Decreased potency of fimasartan in liver cirrhosis was quantified using mixed-effects analysis. Translational and Clinical Pharmacology, 2017, 25, 43.	0.3	1
47	Pharmacokinetic drug interaction between atorvastatin and ezetimibe in healthy Korean volunteers. Translational and Clinical Pharmacology, 2017, 25, 202.	0.3	6
48	Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the <em>SLCO1B1</em> or <em>CYP2C9</em> genetic polymorphism affect these drug interactions?. Drug Design, Development and Therapy, 2017, Volume11, 503-512.	2.0	9
49	Clinical Pharmacokinetics of Caffeine in Korean Preterm Infants with Apnea of Prematurity. Neonatal Medicine, 2017, 24, 20.	0.1	3
50	Effects of JOINSÂ $^{\circ}$ on the pharmacokinetic profiles of aceclofenac in healthy Korean volunteers: an open-label, multiple-dose, one sequence, two-period study. Translational and Clinical Pharmacology, 2016, 24, 169.	0.3	1
51	A Case of Pulmonary Interstitial Emphysema Treated by Percutaneous Catheter Insertion in Extremely Low Birth Weight Infant. Yonsei Medical Journal, 2016, 57, 1523.	0.9	7
52	Clinical Outcomes of Renal Pelvis Dilatation in Very Low Birth Weight Infants. Perinatology, 2016, 27, 244.	0.0	0
53	Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects. Drug Design, Development and Therapy, 2016, Volume 10, 3763-3770.	2.0	2
54	Pharmacokinetics and safety profiles of tadalafil/tamsulosin HCl fixed-dose combination capsule under fasted and fed condition in healthy volunteers. Translational and Clinical Pharmacology, 2016, 24, 175.	0.3	1

#	Article	IF	CITATIONS
55	Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses. Leukemia and Lymphoma, 2016, 57, 1856-1864.	0.6	8
56	Diagnosis of Severe Protein C Deficiency Confirmed by Presence of RarePROCGene Mutation. Neonatal Medicine, 2016, 23, 233.	0.1	2
57	The efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia. Korean Journal of Pediatrics, 2015, 58, 347.	1.9	13
58	Efficacy and Safety of Kangaroo Mother Care in Preterm Infants in Korea. Korean Journal of Perinatology, 2015, 26, 305.	0.1	6
59	Pharmacokinetic Interaction Between Amlodipine and Lobeglitazone, a Novel Peroxisome Proliferator–activated Receptor-γ Agonist, in Healthy Subjects. Clinical Therapeutics, 2015, 37, 1999-2006.e1.	1.1	12
60	Usefulness of serum cystatin C to determine the dose of vancomycin in neonate. Korean Journal of Pediatrics, 2015, 58, 421.	1.9	6
61	Intracranial Pial Arteriovenous Fistula Presenting as Brain Hemorrhage in Newborn Infants. Neonatal Medicine, 2015, 22, 228.	0.1	3
62	Risk Factors for Rickets of Prematurity in Extremely Low Birth Weight Infants. Neonatal Medicine, 2015, 22, 192.	0.1	1
63	Risk Factors for Postoperative Cardiopulmonary Instability Following Ligation of Patent Ductus Arteriosus in Very Low Birth Weight Infants. Neonatal Medicine, 2015, 22, 198.	0.1	0
64	Positive Maternal C-Reactive Protein Predicts Neonatal Sepsis. Yonsei Medical Journal, 2014, 55, 113.	0.9	14
65	Nutritional Outcomes in Children with Epidermolysis Bullosa: The Experiences of Two Centers in Korea. Yonsei Medical Journal, 2014, 55, 264.	0.9	13
66	Firstâ€inâ€human study with new recombinant agalsidase beta (ISU303) in healthy subjects. Journal of Clinical Pharmacology, 2014, 54, 675-681.	1.0	4
67	Pregnane X Receptor agonist Increases the Expression Levels of the Plasma Membrane Monoamine Transporter. Translational and Clinical Pharmacology, 2014, 22, 19.	0.3	0
68	Effect of Ketoconazole on Lobeglitazone Pharmacokinetics in Korean Volunteers. Clinical Therapeutics, 2014, 36, 1064-1071.	1.1	5
69	Combination Therapies of Amiodarone and Digoxin for Refractory Supraventricular Tachycardia Accompanied by Congenital Heart Diseases in a Preterm Infant with Hydrops Fetalis. Neonatal Medicine, 2014, 21, 52.	0.1	0
70	Off-label use and designation of age groupspecific contraindications for pharmacotherapy in children in Korea. Translational and Clinical Pharmacology, 2014, 22, 58.	0.3	0
71	Autosomal Recessive Polycystic Kidney Disease Confirmed toPKHD1Gene Mutation: A Case ofPKHD1Gene Mutation. Neonatal Medicine, 2014, 21, 64.	0.1	1
72	Usefulness of the delta neutrophil index for assessing neonatal sepsis. Acta Paediatrica, International Journal of Paediatrics, 2013, 102, e13-6.	0.7	21

#	Article	IF	CITATIONS
73	Influence of Hepatic Dysfunction on the Pharmacokinetics and Safety of Fimasartan. Journal of Cardiovascular Pharmacology, 2013, 62, 524-529.	0.8	9
74	Impact of ABCC2, ABCG2 and SLCO1B1 Polymorphisms on the Pharmacokinetics of Pitavastatin in Humans. Drug Metabolism and Pharmacokinetics, 2013, 28, 196-202.	1.1	36
75	Parenteral Nutrition Associated Cholestasis Is Earlier, More Prolonged and Severe in Small for Gestational Age Compared with Appropriate for Gestational Age Very Low Birth Weight Infants. Yonsei Medical Journal, 2013, 54, 839.	0.9	10
76	Serological investigation of Ureaplasma urealyticumin Korean preterm infants. Korean Journal of Pediatrics, 2013, 56, 477.	1.9	4
77	Metabolic Bone Disease of Prematurity. Neonatal Medicine, 2013, 20, 276.	0.1	2
78	Risk Factors of Pulmonary Hypertension in Preterm Infants with Chronic Lung Disease. Neonatal Medicine, 2013, 20, 75.	0.1	2
79	Meconium-related lleus in Extremely Low-birth Weight Newborn Infants Meconium-related lleus in ELBWI. Neonatal Medicine, 2013, 20, 121.	0.1	3
80	Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures. Archives of Disease in Childhood, 2012, 97, 569-572.	1.0	14
81	The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers. Pharmacogenetics and Genomics, 2012, 22, 598-605.	0.7	35
82	Change in Prostaglandin Expression Levels and Synthesizing Activities in Dry Eye Disease. Ophthalmology, 2012, 119, 2211-2219.	2.5	54
83	The views of patients and healthy volunteers on participation in clinical trials: An exploratory survey study. Contemporary Clinical Trials, 2012, 33, 611-619.	0.8	27
84	Effect of <i>HMGCR</i> Variant Alleles on Lowâ€Density Lipoprotein Cholesterol—Lowering Response to Atorvastatin in Healthy Korean Subjects. Journal of Clinical Pharmacology, 2012, 52, 339-346.	1.0	26
85	Chemerin and Adiponectin Contribute Reciprocally to Metabolic Syndrome. PLoS ONE, 2012, 7, e34710.	1.1	80
86	High Incidence of Rickets in Extremely Low Birth Weight Infants with Severe Parenteral Nutrition-Associated Cholestasis and Bronchopulmonary Dysplasia. Journal of Korean Medical Science, 2012, 27, 1552.	1.1	23
87	Successful pleurodesis with OK-432 in preterm infants with persistent pleural effusion. Korean Journal of Pediatrics, 2012, 55, 177.	1.9	22
88	Modeling of the LDL cholesterol-lowering effect of atorvastatin in Korean dyslipidemic patients and non-patient volunteers. International Journal of Clinical Pharmacology and Therapeutics, 2012, 50, 647-656.	0.3	5
89	Risk of Surgery for Retinopathy of Prematurity in Very Low Birth Weight Infants. Journal of the Korean Society of Neonatology, 2012, 19, 71.	0.3	3
90	Effect of CYP2B6 Genotype on the Pharmacokinetics of Sibutramine and Active Metabolites in Healthy Subjects. Journal of Clinical Pharmacology, 2011, 51, 53-59.	1.0	14

#	Article	IF	CITATIONS
91	X-linked Myotubular Myopathy in a Family with Two Infant Siblings: A Case withMTM1Mutation. Yonsei Medical Journal, 2011, 52, 547.	0.9	5
92	Physicians' roles in biopharmaceutical industry for global competition. Journal of the Korean Medical Association, 2011, 54, 570.	0.1	0
93	Pharmacokinetic Comparison of Sustained- and Immediate-Release Oral Formulations of Cilostazol in Healthy Korean Subjects: A Randomized, Open-Label, 3-Part, Sequential, 2-Period, Crossover, Single-Dose, Food-Effect, and Multiple-Dose Study. Clinical Therapeutics, 2011, 33, 2038-2053.	1.1	12
94	5-Lipoxygenase-Activating Protein (FLAP) Inhibitor MK-0591 Prevents Aberrant Alveolarization in Newborn Mice Exposed to 85% Oxygen in a Dose- and Time-Dependent Manner. Lung, 2011, 189, 43-50.	1.4	3
95	CYP3A5*3 Genotype Associated With Intrasubject Pharmacokinetic Variation Toward Tacrolimus in Bioequivalence Study. Therapeutic Drug Monitoring, 2010, 32, 67-72.	1.0	30
96	Survival analysis of spinal muscular atrophy type I. Korean Journal of Pediatrics, 2010, 53, 965.	1.9	16
97	Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: A randomized, open-label, parallel-group, single- and multiple-dose study. Clinical Therapeutics, 2010, 32, 206-216.	1.1	18
98	A case of postoperative nasopharyngeal reflux associated with retropharyngeal lymphangioma in newborn infant. Korean Journal of Pediatrics, 2010, 53, 258.	1.9	1
99	Effect of severe neonatal morbidities on long term outcome in extremely low birthweight infants. Korean Journal of Pediatrics, 2010, 53, 694.	1.9	18
100	A Case of Suspected Isotretinoin-Induced Malformation in a Baby of a Mother Who Became Pregnant One Month after Discontinuation of the Drug. Yonsei Medical Journal, 2009, 50, 445.	0.9	15
101	Montelukast as an add-on therapy in bronchopulmonary dysplasia. Korean Journal of Pediatrics, 2009, 52, 181.	1.9	4
102	De novo interstitial direct duplication 8 (p21.3p23.1) with Pierre Robin sequence. Korean Journal of Pediatrics, 2009, 52, 603.	1.9	0
103	Clinical experience of therapeutic effect of peritoneal drainage on intestinal perforation in preterm infants. Korean Journal of Pediatrics, 2009, 52, 1216.	1.9	0
104	Could lipid infusion be a risk for parenteral nutrition-associated cholestasis in low birth weight neonates?. European Journal of Pediatrics, 2008, 167, 197-202.	1.3	50
105	Immunoprophylaxis failure against vertical transmission of hepatitis B virus: what is the mechanism and do other factors also play a role?. European Journal of Pediatrics, 2008, 167, 489-490.	1.3	3
106	Effect of surfactant lavage in severe meconium aspiration syndrome. Korean Journal of Pediatrics, 2008, 51, 367.	1.9	8
107	Oxygenation index as a respiratory parameter of respiratory distress syndrome in preterm infants. Korean Journal of Pediatrics, 2008, 51, 145.	1.9	2
108	Altered Expressions of Fibroblast Growth Factor Receptors and Alveolarization in Neonatal Mice Exposed to 85% Oxygen. Pediatric Research, 2007, 62, 652-657.	1.1	49

#	Article	IF	Citations
109	A randomized, open-label, two-period, crossover bioavailability study of two oral formulations of tacrolimus in healthy Korean adults. Clinical Therapeutics, 2007, 29, 154-162.	1.1	26
110	The effect of restricted fluid intakes in the first week of life on the risk of bronchopulmonary dysplasia and patent ductus arteriosus in very low birth weight infants. Korean Journal of Pediatrics, 2007, 50, 536.	1.9	1
111	Transabdominal Embryofetoscopy for the Detection of Short Rib-polydactyly Syndrome, Type II(Majewski), in the First Trimester. Journal of Korean Medical Science, 2006, 21, 165.	1.1	4
112	Compartmental inhibition of hepatic glutathione reductase activities by 1,3-bis(2-chloroethyl)-N-nitrosourea (BCNU) in Sprague–Dawley and Fischer-344 rats. Toxicology Letters, 2004, 147, 219-228.	0.4	13
113	Primary Humoral Immune Responses to Formalin Inactivated Hemorrhagic Fever with Renal Syndrome Vaccine (Hantavax $\hat{A}^{0}$ ): Consideration of Active Immunization in South Korea. Yonsei Medical Journal, 2001, 42, 278.	0.9	39
114	A Case of del(13)(q22) with Multiple Major Congenital Anomalies, Imperforate Anus and Penoscrotal Transposition. Yonsei Medical Journal, 2001, 42, 558.	0.9	12
115	The changing epidemiology of hepatitis A in children and the consideration of active immunization in Korea. Yonsei Medical Journal, 2000, 41, 34.	0.9	63
116	Prospective evaluation of perinatal risk factors for cerebral palsy and delayed development in high risk infants. Yonsei Medical Journal, 1999, 40, 363.	0.9	14
117	Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants. Vaccine, 1999, 17, 2259-2264.	1.7	65
118	Development of A New Adverse Drug Reaction Monitoring System in General Hospital and Evaluation of its Outcome. Journal of Korean Society of Medical Informatics, 1999, 5, 149.	0.3	2
119	Antibiotic use at a pediatric age. Yonsei Medical Journal, 1998, 39, 595.	0.9	6
120	Hyperoxia influences mRNA expression of cytokines in cultured human umbilical vein endothelial cells. Yonsei Medical Journal, 1998, 39, 1.	0.9	4
121	A Seroepidemiologic Study of Hepatitis A Virus in the Healthy Children and Adolescent in Kyonggi-do Province. Korean Journal of Pediatric Infectious Diseases, 1997, 4, 232.	0.1	12
122	Pediatric Clinical Pharmacology. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 1996, 4, 239.	0.1	0
123	Diagnostic value of insulin-like growth factor-l in short stature. Yonsei Medical Journal, 1989, 30, 367.	0.9	2